0.00Open2.19Pre Close0 Volume344 Open Interest5.00Strike Price0.00Turnover1156.50%IV9.21%PremiumOct 18, 2024Expiry Date1.91Intrinsic Value100Multiplier0DDays to Expiry0.29Extrinsic Value100Contract SizeAmericanOptions Type-0.9304Delta0.1467Gamma1.51Leverage Ratio-0.2466Theta0.0000Rho-1.40Eff Leverage0.0001Vega
Organogenesis Stock Discussion
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
• Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04)
• Organogenesis believes published study satisfies requirements for Medicare coverage under proposed Local Coverage Determination (LCDs)
CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) ...
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
No comment yet